Cargando…

Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening

BACKGROUND: Lung cancer is a major cause of cancer-related mortality worldwide, and around two-thirds of patients have metastasis at diagnosis. Thus, detecting lung cancer at an early stage could reduce mortality. Aberrant levels of circulating small non-coding RNAs (small ncRNAs) are potential diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Yuhong, Zhu, Yong, Ai, Junmei, Chen, Hankui, Liu, Helu, Borgia, Jeffrey A., Li, Xiao, Yang, Fan, Jiang, Bin, Wang, Jun, Deng, Youping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053820/
https://www.ncbi.nlm.nih.gov/pubmed/30029594
http://dx.doi.org/10.1186/s12864-018-4862-z
_version_ 1783340899386785792
author Dou, Yuhong
Zhu, Yong
Ai, Junmei
Chen, Hankui
Liu, Helu
Borgia, Jeffrey A.
Li, Xiao
Yang, Fan
Jiang, Bin
Wang, Jun
Deng, Youping
author_facet Dou, Yuhong
Zhu, Yong
Ai, Junmei
Chen, Hankui
Liu, Helu
Borgia, Jeffrey A.
Li, Xiao
Yang, Fan
Jiang, Bin
Wang, Jun
Deng, Youping
author_sort Dou, Yuhong
collection PubMed
description BACKGROUND: Lung cancer is a major cause of cancer-related mortality worldwide, and around two-thirds of patients have metastasis at diagnosis. Thus, detecting lung cancer at an early stage could reduce mortality. Aberrant levels of circulating small non-coding RNAs (small ncRNAs) are potential diagnostic or prognostic markers for lung cancer. We aimed to identify plasma small ncRNA pairs that could be used for early screening and detection of lung adenocarcinoma (LAC). RESULTS: A panel of seven small ncRNA pair ratios could differentiate patients with LAC or benign lung disease from high-risk controls with an area under the curve (AUC) of 100.0%, a sensitivity of 100.0% and a specificity of 100.0% at the training stage (which included 50 patients with early-stage LAC, 35 patients with benign diseases and 29 high-risk controls) and an AUC of 90.2%, a sensitivity of 91.5% and a specificity of 80.4% at the validation stage (which included 44 patients with early-stage LAC, 32 patients with benign diseases and 51 high-risk controls). The same panel could distinguish LAC from high-risk controls with an AUC of 100.0%, a sensitivity of 100.0% and a specificity of 100.0% at the training stage and an AUC of 89.5%, a sensitivity of 85.4% and a specificity of 83.3% at the validation stage. Another panel of five small ncRNA pair ratios (different from the first) was able to differentiate LAC from benign disease with an AUC of 82.0%, a sensitivity of 81.1% and a specificity of 78.1% in the training cohort and an AUC of 74.2%, a sensitivity of 70.4% and a specificity of 72.7% in the validation cohort. CONCLUSIONS: Several small ncRNA pair ratios were identified as markers capable of discerning patients with LAC from those with benign lesions or high-risk control individuals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12864-018-4862-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6053820
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60538202018-07-23 Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening Dou, Yuhong Zhu, Yong Ai, Junmei Chen, Hankui Liu, Helu Borgia, Jeffrey A. Li, Xiao Yang, Fan Jiang, Bin Wang, Jun Deng, Youping BMC Genomics Research Article BACKGROUND: Lung cancer is a major cause of cancer-related mortality worldwide, and around two-thirds of patients have metastasis at diagnosis. Thus, detecting lung cancer at an early stage could reduce mortality. Aberrant levels of circulating small non-coding RNAs (small ncRNAs) are potential diagnostic or prognostic markers for lung cancer. We aimed to identify plasma small ncRNA pairs that could be used for early screening and detection of lung adenocarcinoma (LAC). RESULTS: A panel of seven small ncRNA pair ratios could differentiate patients with LAC or benign lung disease from high-risk controls with an area under the curve (AUC) of 100.0%, a sensitivity of 100.0% and a specificity of 100.0% at the training stage (which included 50 patients with early-stage LAC, 35 patients with benign diseases and 29 high-risk controls) and an AUC of 90.2%, a sensitivity of 91.5% and a specificity of 80.4% at the validation stage (which included 44 patients with early-stage LAC, 32 patients with benign diseases and 51 high-risk controls). The same panel could distinguish LAC from high-risk controls with an AUC of 100.0%, a sensitivity of 100.0% and a specificity of 100.0% at the training stage and an AUC of 89.5%, a sensitivity of 85.4% and a specificity of 83.3% at the validation stage. Another panel of five small ncRNA pair ratios (different from the first) was able to differentiate LAC from benign disease with an AUC of 82.0%, a sensitivity of 81.1% and a specificity of 78.1% in the training cohort and an AUC of 74.2%, a sensitivity of 70.4% and a specificity of 72.7% in the validation cohort. CONCLUSIONS: Several small ncRNA pair ratios were identified as markers capable of discerning patients with LAC from those with benign lesions or high-risk control individuals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12864-018-4862-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-20 /pmc/articles/PMC6053820/ /pubmed/30029594 http://dx.doi.org/10.1186/s12864-018-4862-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Dou, Yuhong
Zhu, Yong
Ai, Junmei
Chen, Hankui
Liu, Helu
Borgia, Jeffrey A.
Li, Xiao
Yang, Fan
Jiang, Bin
Wang, Jun
Deng, Youping
Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title_full Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title_fullStr Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title_full_unstemmed Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title_short Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
title_sort plasma small ncrna pair panels as novel biomarkers for early-stage lung adenocarcinoma screening
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053820/
https://www.ncbi.nlm.nih.gov/pubmed/30029594
http://dx.doi.org/10.1186/s12864-018-4862-z
work_keys_str_mv AT douyuhong plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT zhuyong plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT aijunmei plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT chenhankui plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT liuhelu plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT borgiajeffreya plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT lixiao plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT yangfan plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT jiangbin plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT wangjun plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening
AT dengyouping plasmasmallncrnapairpanelsasnovelbiomarkersforearlystagelungadenocarcinomascreening